Abstract Background The source of ninjin'yoeito (NYT) is considered the ‘Formulary of Bureau of Taiping People's Welfare Pharmacy’, written around 1241–52 AD. NYT is used to treat patients with chronic fatigue, malaise with qi deficiency, and exhaustion of all five parenchymatous viscera with difficulty in recovering. Key Findings NYT formula consists of 12 crude drugs. NYT extract for medical use is covered by the National Health Insurance system of Japan for convalescence after recovery from diseases, fatigue and malaise, anorexia, perspiration during sleep, cold limbs, and anemia. Studies have shown clinical effects of NYT: treatment of anemia, cancer treatment support, frailty, cognitive dysfunction, apathy, fatigue/malaise, anorexia, and lung diseases. Preclinical studies support clinical studies; activating ghrelin‐neuropeptide Y pathway‐mediated appetite‐enhancing effects, inhibiting muscle volume loss through the Akt/mTOR pathway‐mediated hyperphosphorylation of 4E‐BP1 and FoxO1‐mediated Atrogin‐1, suppressing the hypothalamic–pituitary–adrenal axis by downregulating the sympathetic‐adrenal‐medullary axis and GABA neurons for improving sociability, promoting recovery from skeletal muscle atrophy through the activation of PGC‐1α, hematopoiesis‐promoting effects, and increasing the number of immune cells in immunocompromised models. The incidence of adverse events of NYT was reported as 3.09 or 2.03%. The most significant adverse effects of NYT are gastrointestinal disorders. Conclusion Recently, NYT has been widely used to treat several symptoms and conditions under the National Health Insurance System of Japan. Clinical studies showed the efficacy of NYT to treat anemia, frailty, cognitive dysfunction, anorexia, apathy, and fatigue/malaise, as well as for long‐term cancer treatment support. The pharmacological mechanisms supporting its effects are also being reported.
{"title":"Review of frequently used Kampo prescriptions: Part 4, Ninjin'yoeito","authors":"Shin Takayama, Seiwa Michihara, Yoko Kimura, Akinori Morinaga, Kyohei Miyakawa, Nobuhiko Tsushima, Kahori Otani, Atsuko Jinnai, Yuko Aso, Asako Okabayashi, Ryutaro Arita, Tatsuya Nogami, Akio Inui","doi":"10.1002/tkm2.1387","DOIUrl":"https://doi.org/10.1002/tkm2.1387","url":null,"abstract":"Abstract Background The source of ninjin'yoeito (NYT) is considered the ‘Formulary of Bureau of Taiping People's Welfare Pharmacy’, written around 1241–52 AD. NYT is used to treat patients with chronic fatigue, malaise with qi deficiency, and exhaustion of all five parenchymatous viscera with difficulty in recovering. Key Findings NYT formula consists of 12 crude drugs. NYT extract for medical use is covered by the National Health Insurance system of Japan for convalescence after recovery from diseases, fatigue and malaise, anorexia, perspiration during sleep, cold limbs, and anemia. Studies have shown clinical effects of NYT: treatment of anemia, cancer treatment support, frailty, cognitive dysfunction, apathy, fatigue/malaise, anorexia, and lung diseases. Preclinical studies support clinical studies; activating ghrelin‐neuropeptide Y pathway‐mediated appetite‐enhancing effects, inhibiting muscle volume loss through the Akt/mTOR pathway‐mediated hyperphosphorylation of 4E‐BP1 and FoxO1‐mediated Atrogin‐1, suppressing the hypothalamic–pituitary–adrenal axis by downregulating the sympathetic‐adrenal‐medullary axis and GABA neurons for improving sociability, promoting recovery from skeletal muscle atrophy through the activation of PGC‐1α, hematopoiesis‐promoting effects, and increasing the number of immune cells in immunocompromised models. The incidence of adverse events of NYT was reported as 3.09 or 2.03%. The most significant adverse effects of NYT are gastrointestinal disorders. Conclusion Recently, NYT has been widely used to treat several symptoms and conditions under the National Health Insurance System of Japan. Clinical studies showed the efficacy of NYT to treat anemia, frailty, cognitive dysfunction, anorexia, apathy, and fatigue/malaise, as well as for long‐term cancer treatment support. The pharmacological mechanisms supporting its effects are also being reported.","PeriodicalId":23213,"journal":{"name":"Traditional & Kampo Medicine","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-10-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135254115","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Traditional & Kampo MedicineEarly View LETTER TO THE EDITOR Three cases successfully treated with a combination of unkeito and boiogito for menopausal arthralgia Daigo Taniguchi, Daigo Taniguchi Department of Psychosomatic Medicine, Graduate School of Medical Sciences, Kyushu University, Fukuoka, JapanSearch for more papers by this authorTatsuya Nogami, Corresponding Author Tatsuya Nogami [email protected] orcid.org/0000-0002-9724-4356 Department of Kampo Medicine, Tokai University School of Medicine, Isehara, Japan Department of Kampo Medicine, Tomei Atsugi Clinic, Atsugi, Japan Correspondence Tatsuya Nogami, Department of Kampo Medicine, Tokai University School of Medicine, Isehara, Japan. Email: [email protected]Search for more papers by this authorNoriko Miyatake, Noriko Miyatake Department of Kampo Medicine, Tokai University School of Medicine, Isehara, JapanSearch for more papers by this authorToko Tsuruta, Toko Tsuruta Department of Obstetrics and Gynecology, Kofukyoritsu Hospital, Kofu, JapanSearch for more papers by this authorMakoto Arai, Makoto Arai Department of Kampo Medicine, Tokai University School of Medicine, Isehara, JapanSearch for more papers by this author Daigo Taniguchi, Daigo Taniguchi Department of Psychosomatic Medicine, Graduate School of Medical Sciences, Kyushu University, Fukuoka, JapanSearch for more papers by this authorTatsuya Nogami, Corresponding Author Tatsuya Nogami [email protected] orcid.org/0000-0002-9724-4356 Department of Kampo Medicine, Tokai University School of Medicine, Isehara, Japan Department of Kampo Medicine, Tomei Atsugi Clinic, Atsugi, Japan Correspondence Tatsuya Nogami, Department of Kampo Medicine, Tokai University School of Medicine, Isehara, Japan. Email: [email protected]Search for more papers by this authorNoriko Miyatake, Noriko Miyatake Department of Kampo Medicine, Tokai University School of Medicine, Isehara, JapanSearch for more papers by this authorToko Tsuruta, Toko Tsuruta Department of Obstetrics and Gynecology, Kofukyoritsu Hospital, Kofu, JapanSearch for more papers by this authorMakoto Arai, Makoto Arai Department of Kampo Medicine, Tokai University School of Medicine, Isehara, JapanSearch for more papers by this author First published: 03 October 2023 https://doi.org/10.1002/tkm2.1390Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onEmailFacebookTwitterLinkedInRedditWechat No abstract is available for this article. REFERENCES 1Magliano M. Menopausal arthralgia: fact or fiction. Maturitas. 2010; 67(1): 29–33. https://doi.org/10.1016/j.maturi
{"title":"Three cases successfully treated with a combination of unkeito and boiogito for menopausal arthralgia","authors":"Daigo Taniguchi, Tatsuya Nogami, Noriko Miyatake, Toko Tsuruta, Makoto Arai","doi":"10.1002/tkm2.1390","DOIUrl":"https://doi.org/10.1002/tkm2.1390","url":null,"abstract":"Traditional & Kampo MedicineEarly View LETTER TO THE EDITOR Three cases successfully treated with a combination of unkeito and boiogito for menopausal arthralgia Daigo Taniguchi, Daigo Taniguchi Department of Psychosomatic Medicine, Graduate School of Medical Sciences, Kyushu University, Fukuoka, JapanSearch for more papers by this authorTatsuya Nogami, Corresponding Author Tatsuya Nogami [email protected] orcid.org/0000-0002-9724-4356 Department of Kampo Medicine, Tokai University School of Medicine, Isehara, Japan Department of Kampo Medicine, Tomei Atsugi Clinic, Atsugi, Japan Correspondence Tatsuya Nogami, Department of Kampo Medicine, Tokai University School of Medicine, Isehara, Japan. Email: [email protected]Search for more papers by this authorNoriko Miyatake, Noriko Miyatake Department of Kampo Medicine, Tokai University School of Medicine, Isehara, JapanSearch for more papers by this authorToko Tsuruta, Toko Tsuruta Department of Obstetrics and Gynecology, Kofukyoritsu Hospital, Kofu, JapanSearch for more papers by this authorMakoto Arai, Makoto Arai Department of Kampo Medicine, Tokai University School of Medicine, Isehara, JapanSearch for more papers by this author Daigo Taniguchi, Daigo Taniguchi Department of Psychosomatic Medicine, Graduate School of Medical Sciences, Kyushu University, Fukuoka, JapanSearch for more papers by this authorTatsuya Nogami, Corresponding Author Tatsuya Nogami [email protected] orcid.org/0000-0002-9724-4356 Department of Kampo Medicine, Tokai University School of Medicine, Isehara, Japan Department of Kampo Medicine, Tomei Atsugi Clinic, Atsugi, Japan Correspondence Tatsuya Nogami, Department of Kampo Medicine, Tokai University School of Medicine, Isehara, Japan. Email: [email protected]Search for more papers by this authorNoriko Miyatake, Noriko Miyatake Department of Kampo Medicine, Tokai University School of Medicine, Isehara, JapanSearch for more papers by this authorToko Tsuruta, Toko Tsuruta Department of Obstetrics and Gynecology, Kofukyoritsu Hospital, Kofu, JapanSearch for more papers by this authorMakoto Arai, Makoto Arai Department of Kampo Medicine, Tokai University School of Medicine, Isehara, JapanSearch for more papers by this author First published: 03 October 2023 https://doi.org/10.1002/tkm2.1390Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onEmailFacebookTwitterLinkedInRedditWechat No abstract is available for this article. REFERENCES 1Magliano M. Menopausal arthralgia: fact or fiction. Maturitas. 2010; 67(1): 29–33. https://doi.org/10.1016/j.maturi","PeriodicalId":23213,"journal":{"name":"Traditional & Kampo Medicine","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-10-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135696461","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Abstract Aim This study aimed to clarify the safety of Valeriana fauriei root (VF) ethanol extract through in vivo and clinical trials. Methods Mice were divided into VF and control groups. They were given VF (4 g VF/kg/day) or the vehicle mixed in the powdered food for four weeks. Food consumption and body weight changes were evaluated, and blood biochemistry and organ weights were assessed on the last day. In addition, an open‐label study was conducted on healthy subjects who took VF capsules (10 g VF/body/day) for four weeks and were asked to report any changes in their physical condition. Physical, hematologic, blood biochemical examination and urinalysis were performed before, two weeks, and four weeks into the study. Results Food consumption and weight gain in mice did not differ between the VF and control groups, except for experimental error, and there were no particular differences in the weights of the brain, lung, heart, liver, spleen, and kidney. In mice, VF administration resulted in small but significant decreases in albumin in males and females, and total cholesterol and high‐density lipoprotein cholesterol in females only. These levels were unchanged, but daytime sleepiness was observed in humans. Conclusion Since there was little change in the experimental values at continuous high doses of VF at 10 g/day, it can be concluded that approximately one‐fifth of this dose (2 g VF/day) is less harmful. However, daytime sleepiness should be considered.
摘要目的通过体内试验和临床试验，阐明缬草根(VF)乙醇提取物的安全性。方法将小鼠分为VF组和对照组。分别给予VF (4 g VF/kg/天)或混合在粉状食品中的整车，连续4周。在最后一天评估食物消耗和体重变化，并评估血液生化和器官重量。此外，对健康受试者进行了一项开放标签研究，他们连续四周服用VF胶囊(10g VF/body/day)，并被要求报告其身体状况的任何变化。研究开始前、2周和4周分别进行生理、血液学、血液生化检查和尿液分析。结果除实验误差外，VF组和对照组小鼠的食量和体重增加没有差异，脑、肺、心、肝、脾和肾的重量也没有特别的差异。在小鼠中，给药VF导致雄性和雌性小鼠白蛋白和总胆固醇和高密度脂蛋白胆固醇的小幅但显著下降。这些水平没有变化，但在人类中观察到白天嗜睡。结论:在10 g/天的连续高剂量VF下，实验值几乎没有变化，因此可以得出结论，大约五分之一的剂量(2 g VF/天)的危害较小。然而，白天的嗜睡应该被考虑在内。
{"title":"Safety evaluation of continuous administration of a high dose of <i>Valeriana fauriei</i> root extract in mice and in humans through an open‐label study","authors":"Misato Ota, Yuki Oiwa, Yasuhito Maki, Ichiro Utaka, Sachie Arima, Yoichi Matsuo, Toshiaki Makino, Shunsuke Nojiri","doi":"10.1002/tkm2.1388","DOIUrl":"https://doi.org/10.1002/tkm2.1388","url":null,"abstract":"Abstract Aim This study aimed to clarify the safety of Valeriana fauriei root (VF) ethanol extract through in vivo and clinical trials. Methods Mice were divided into VF and control groups. They were given VF (4 g VF/kg/day) or the vehicle mixed in the powdered food for four weeks. Food consumption and body weight changes were evaluated, and blood biochemistry and organ weights were assessed on the last day. In addition, an open‐label study was conducted on healthy subjects who took VF capsules (10 g VF/body/day) for four weeks and were asked to report any changes in their physical condition. Physical, hematologic, blood biochemical examination and urinalysis were performed before, two weeks, and four weeks into the study. Results Food consumption and weight gain in mice did not differ between the VF and control groups, except for experimental error, and there were no particular differences in the weights of the brain, lung, heart, liver, spleen, and kidney. In mice, VF administration resulted in small but significant decreases in albumin in males and females, and total cholesterol and high‐density lipoprotein cholesterol in females only. These levels were unchanged, but daytime sleepiness was observed in humans. Conclusion Since there was little change in the experimental values at continuous high doses of VF at 10 g/day, it can be concluded that approximately one‐fifth of this dose (2 g VF/day) is less harmful. However, daytime sleepiness should be considered.","PeriodicalId":23213,"journal":{"name":"Traditional & Kampo Medicine","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-10-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135828784","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Abstract Aim 5‐Fluorouracil/folinic acid and oxaliplatin plus bevacizumab (FOLFOX + BV) is a standard chemotherapy regimen for metastatic colorectal cancer (mCRC). This study was aimed at evaluating the preventive effects of shakuyakukanzoto against oxaliplatin‐induced neurotoxicity associated with FOLFOX + BV administration. Methods In this single‐arm, open‐label, phase II clinical trial, we enrolled patients with previously untreated, histologically confirmed mCRC from six hospitals in Japan who were aged 20 years and older and had an Eastern Cooperative Oncology Group performance status of 0–1. The patients received shakuyakukanzoto 2.5 g thrice daily, orally, until disease progression and/or unacceptable toxicity was noted. The primary endpoint was the incidence of neurotoxicity following oxaliplatin administration at a dose of 500 mg/m 2 . Neurotoxicity was evaluated according to the Neurotoxicity Criteria of Debiopharm (DEB‐NTC). The trial was registered in the UMIN Clinical Trials Registry of Japan (UMIN000001853). Results Forty‐one non‐pretreated mCRC patients were included between April 2009 and September 2013. At an oxaliplatin dose of 500 mg/m 2 , neurotoxicity of DEB‐NTC grade 1–2 developed in 25.0% of patients; no patient had DEB‐NTC grade 3 neurotoxicity. The most common grade 3/4 adverse events were neutropenia (34.1%), hypertension (24.4%), and fatigue (9.8%). The response rate of the 38 patients with measurable lesions was 55.2%. The median progression‐free and overall survival was 14.9 and 35.2 months respectively. Conclusion Shakuyakukanzoto substantially reduced oxaliplatin‐induced neurotoxicity without negatively affecting tumor response or survival in FOLFOX + BV‐treated patients with CRC.
{"title":"Preventive effect of a traditional Japanese Kampo medicine, <i>shakuyakukanzoto</i>, against neurotoxicity of <scp>FOLFOX</scp> plus bevacizumab used for metastatic colorectal cancer management: A single‐arm phase <scp>II</scp> study","authors":"Hiroaki Takagi, Shinya Kajiura, Ayumu Hosokawa, Naoki Horikawa, Itsuro Terada, Taishi Hata, Yuka Kobayashi, Yuji Tsukioka, Kazuhisa Yabushita, Takashi Matsuo, Hiroki Yoshita, Akira Ueda, Kohei Ogawa, Takayuki Ando, Ryuji Hayashi, Ichiro Yasuda","doi":"10.1002/tkm2.1389","DOIUrl":"https://doi.org/10.1002/tkm2.1389","url":null,"abstract":"Abstract Aim 5‐Fluorouracil/folinic acid and oxaliplatin plus bevacizumab (FOLFOX + BV) is a standard chemotherapy regimen for metastatic colorectal cancer (mCRC). This study was aimed at evaluating the preventive effects of shakuyakukanzoto against oxaliplatin‐induced neurotoxicity associated with FOLFOX + BV administration. Methods In this single‐arm, open‐label, phase II clinical trial, we enrolled patients with previously untreated, histologically confirmed mCRC from six hospitals in Japan who were aged 20 years and older and had an Eastern Cooperative Oncology Group performance status of 0–1. The patients received shakuyakukanzoto 2.5 g thrice daily, orally, until disease progression and/or unacceptable toxicity was noted. The primary endpoint was the incidence of neurotoxicity following oxaliplatin administration at a dose of 500 mg/m 2 . Neurotoxicity was evaluated according to the Neurotoxicity Criteria of Debiopharm (DEB‐NTC). The trial was registered in the UMIN Clinical Trials Registry of Japan (UMIN000001853). Results Forty‐one non‐pretreated mCRC patients were included between April 2009 and September 2013. At an oxaliplatin dose of 500 mg/m 2 , neurotoxicity of DEB‐NTC grade 1–2 developed in 25.0% of patients; no patient had DEB‐NTC grade 3 neurotoxicity. The most common grade 3/4 adverse events were neutropenia (34.1%), hypertension (24.4%), and fatigue (9.8%). The response rate of the 38 patients with measurable lesions was 55.2%. The median progression‐free and overall survival was 14.9 and 35.2 months respectively. Conclusion Shakuyakukanzoto substantially reduced oxaliplatin‐induced neurotoxicity without negatively affecting tumor response or survival in FOLFOX + BV‐treated patients with CRC.","PeriodicalId":23213,"journal":{"name":"Traditional & Kampo Medicine","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-09-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"134885547","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Abstract Background The source of yokukansan (YKS) is thought to be Baoying‐Jinjiang (Hoeikinkyōroku in Japanese) by Xue Ji. YKS was originally designed for children and indicated for spasms, clenching of teeth, digestive dysfunction due to mental instability, and insomnia. Key Findings YKS formula consists of seven types of crude drugs. Clinical studies have revealed that YKS exerts physiological effects including the treatment of behavioral and psychiatric symptoms of dementia (BPSD), preoperative sedation and anxiety, and postoperative delirium. A meta‐analysis showed that YKS could improve BPSD and daily living activities; however, no improvement in cognitive function was observed. Preclinical studies have also reported that YKS modulates neuronal pathways in the central nervous system, including the serotonergic, glutamatergic, GABAergic, and other neurotransmitter pathways. The incidence of adverse events associated with YKS was 5.17%, with the major adverse effect being pseudoaldosteronism. Routine blood sampling is considered for hypokalemia prevention. Conclusion YKS is useful for BPSD and perioperative mental instability. The modulation of the serotonergic and glutamatergic neural pathways is one of mechanisms. Pseudoaldosteronism is one of the side effects.
{"title":"A review of frequently used Kampo prescriptions. Part 3. Yokukansan","authors":"Hideaki Yamaguchi, Tetsuhiro Yoshino, Hiroaki Oizumi, Ryutaro Arita, Tatsuya Nogami, Shin Takayama","doi":"10.1002/tkm2.1386","DOIUrl":"https://doi.org/10.1002/tkm2.1386","url":null,"abstract":"Abstract Background The source of yokukansan (YKS) is thought to be Baoying‐Jinjiang (Hoeikinkyōroku in Japanese) by Xue Ji. YKS was originally designed for children and indicated for spasms, clenching of teeth, digestive dysfunction due to mental instability, and insomnia. Key Findings YKS formula consists of seven types of crude drugs. Clinical studies have revealed that YKS exerts physiological effects including the treatment of behavioral and psychiatric symptoms of dementia (BPSD), preoperative sedation and anxiety, and postoperative delirium. A meta‐analysis showed that YKS could improve BPSD and daily living activities; however, no improvement in cognitive function was observed. Preclinical studies have also reported that YKS modulates neuronal pathways in the central nervous system, including the serotonergic, glutamatergic, GABAergic, and other neurotransmitter pathways. The incidence of adverse events associated with YKS was 5.17%, with the major adverse effect being pseudoaldosteronism. Routine blood sampling is considered for hypokalemia prevention. Conclusion YKS is useful for BPSD and perioperative mental instability. The modulation of the serotonergic and glutamatergic neural pathways is one of mechanisms. Pseudoaldosteronism is one of the side effects.","PeriodicalId":23213,"journal":{"name":"Traditional & Kampo Medicine","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-09-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"134886078","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Tomoko Suzuki, Akiko Kikuchi, Akiyo Kaneko, Ryutaro Arita, T. Nogami, Natsumi Saito, S. Takayama
The origin of hangekobokuto (HKT) is from Jin Gui Yao Lue (Kinkiyōryaku in Japanese), and it has been indicated for treating throat discomfort in women.
{"title":"A review of frequently used Kampo prescriptions: Part 2—Hangekobokuto","authors":"Tomoko Suzuki, Akiko Kikuchi, Akiyo Kaneko, Ryutaro Arita, T. Nogami, Natsumi Saito, S. Takayama","doi":"10.1002/tkm2.1373","DOIUrl":"https://doi.org/10.1002/tkm2.1373","url":null,"abstract":"The origin of hangekobokuto (HKT) is from Jin Gui Yao Lue (Kinkiyōryaku in Japanese), and it has been indicated for treating throat discomfort in women.","PeriodicalId":23213,"journal":{"name":"Traditional & Kampo Medicine","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"78174063","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Misato Ota, Yuki Oiwa, Yasuhito Maki, Ichiro Utaka, Sachie Arima, Y. Matsuo, T. Makino, Shunsuke Nojiri
This clinical trial aimed to clarify the sleep‐ameliorating effects of capsules containing Valeriana fauriei root (VF) extract and their adverse effects.
本临床试验旨在阐明缬草根(VF)提取物胶囊的睡眠改善作用及其副作用。
{"title":"Evaluation of capsules containing Valeriana fauriei root extract for sleep improvement: A randomized, double‐blind, placebo‐controlled, cross‐over comparative trial","authors":"Misato Ota, Yuki Oiwa, Yasuhito Maki, Ichiro Utaka, Sachie Arima, Y. Matsuo, T. Makino, Shunsuke Nojiri","doi":"10.1002/tkm2.1382","DOIUrl":"https://doi.org/10.1002/tkm2.1382","url":null,"abstract":"This clinical trial aimed to clarify the sleep‐ameliorating effects of capsules containing Valeriana fauriei root (VF) extract and their adverse effects.","PeriodicalId":23213,"journal":{"name":"Traditional & Kampo Medicine","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-07-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"76482702","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
T. Oikawa, Y. Yakazu, Kazuhiro Hirasawa, Y. Yamaguchi, Yoshimi Harada
To the editor: A muscle cramp is a sudden, spastic, and painful contraction of skeletal muscle, and patients with muscle cramp are frequently seen in clinics. Shakuyakukanzoto (SKT) is a representative Kampo medicine that effectively treats muscle cramps, but it contains a large amount of glycyrrhizin because one of its components is Glycyrrhizae radix. The high incidence of pseudoaldosteronism is therefore a major concern when SKT is used. Recently, we experienced two cases of muscle cramps successfully treated with the Kampo medicine shichimotsukokato (SCMKT), which does not contain Glycyrrhizae radix. Case 1 was a 61-year-old female whose complaint was a 3 month history of muscle cramp in both calves. She suffered from strong muscle cramps approximately three times per week, mainly at nighttime. She also experienced occasional cramping in her fingers or the soles of her feet. Her medical history included breast cancer and lymphedema of the left arm due to surgery. She noted that her skin had become dry, particularly on her hands. Her tongue was light red, with slight white fur. Her pulse was deep and weak. Her abdomen showed moderate abdominal strength accompanied by a slight tympanic sound. After she started taking twice daily doses of SCMKT extract granules (2.5 g per dose), her muscle cramps completely disappeared, with the exception of a single instance the morning after she started SCMKT. One month after the initiation of SCMKT, and at the patient’s request, we prescribed another Kampo medicine, shimotsuto, which has previously been reported to be effective for muscle cramps. This replaced the SCMKT and allowed us to compare its effectiveness with that of SCMKT. After taking shimotsuto for 1 month, the patient reported that she had experienced strong muscle cramps with stiffness in her calves four times during the month. Case 2 was a 68-year-old female with a 10 year history of vertigo and dyspepsia. Kampo treatment, primarily with hangebyakujutsutemmato, had improved these symptoms, but a muscle cramp in her right calf had newly occurred while she was walking and then lasted for 3 months. She thus requested another Kampo medicine to treat the muscle cramp. Her medical history included hypertension, sleep apnea syndrome, and lumbar disc herniation. Her tongue was purple, with thin white fur. Her pulse was deep, and abdominal examination found moderate abdominal strength. After she started taking 4 g of SCMKT extract granules each morning, her muscle cramp disappeared almost entirely. She also reported that her walking speed had become much faster. A muscle cramp is a bothersome symptom, and there are few effective medical treatments for it in modern medicine; however, in Kampo medicine, SKT is widely prescribed in Japan to treat muscle cramps. It is effective for short periods, but an incidence of pseudoaldosteronism as high as 11.1% [1] has been observed in patients administered the full dose. Pseudoaldosteronism occurs due to the glycyr
{"title":"Two cases of muscle cramp successfully treated with shichimotsukokato","authors":"T. Oikawa, Y. Yakazu, Kazuhiro Hirasawa, Y. Yamaguchi, Yoshimi Harada","doi":"10.1002/tkm2.1383","DOIUrl":"https://doi.org/10.1002/tkm2.1383","url":null,"abstract":"To the editor: A muscle cramp is a sudden, spastic, and painful contraction of skeletal muscle, and patients with muscle cramp are frequently seen in clinics. Shakuyakukanzoto (SKT) is a representative Kampo medicine that effectively treats muscle cramps, but it contains a large amount of glycyrrhizin because one of its components is Glycyrrhizae radix. The high incidence of pseudoaldosteronism is therefore a major concern when SKT is used. Recently, we experienced two cases of muscle cramps successfully treated with the Kampo medicine shichimotsukokato (SCMKT), which does not contain Glycyrrhizae radix. Case 1 was a 61-year-old female whose complaint was a 3 month history of muscle cramp in both calves. She suffered from strong muscle cramps approximately three times per week, mainly at nighttime. She also experienced occasional cramping in her fingers or the soles of her feet. Her medical history included breast cancer and lymphedema of the left arm due to surgery. She noted that her skin had become dry, particularly on her hands. Her tongue was light red, with slight white fur. Her pulse was deep and weak. Her abdomen showed moderate abdominal strength accompanied by a slight tympanic sound. After she started taking twice daily doses of SCMKT extract granules (2.5 g per dose), her muscle cramps completely disappeared, with the exception of a single instance the morning after she started SCMKT. One month after the initiation of SCMKT, and at the patient’s request, we prescribed another Kampo medicine, shimotsuto, which has previously been reported to be effective for muscle cramps. This replaced the SCMKT and allowed us to compare its effectiveness with that of SCMKT. After taking shimotsuto for 1 month, the patient reported that she had experienced strong muscle cramps with stiffness in her calves four times during the month. Case 2 was a 68-year-old female with a 10 year history of vertigo and dyspepsia. Kampo treatment, primarily with hangebyakujutsutemmato, had improved these symptoms, but a muscle cramp in her right calf had newly occurred while she was walking and then lasted for 3 months. She thus requested another Kampo medicine to treat the muscle cramp. Her medical history included hypertension, sleep apnea syndrome, and lumbar disc herniation. Her tongue was purple, with thin white fur. Her pulse was deep, and abdominal examination found moderate abdominal strength. After she started taking 4 g of SCMKT extract granules each morning, her muscle cramp disappeared almost entirely. She also reported that her walking speed had become much faster. A muscle cramp is a bothersome symptom, and there are few effective medical treatments for it in modern medicine; however, in Kampo medicine, SKT is widely prescribed in Japan to treat muscle cramps. It is effective for short periods, but an incidence of pseudoaldosteronism as high as 11.1% [1] has been observed in patients administered the full dose. Pseudoaldosteronism occurs due to the glycyr","PeriodicalId":23213,"journal":{"name":"Traditional & Kampo Medicine","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-07-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"73913216","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Several studies have suggested that the known biomarkers and the diagnostic scales are unreliable for the diagnosis of Kampo‐induced liver injury (KMILI).
一些研究表明，已知的生物标志物和诊断量表对于Kampo诱导的肝损伤(KMILI)的诊断不可靠。
{"title":"Overview of diagnostic laboratory tests and diagnostic criteria for liver injury caused by Kampo medicine","authors":"N. Mantani","doi":"10.1002/tkm2.1381","DOIUrl":"https://doi.org/10.1002/tkm2.1381","url":null,"abstract":"Several studies have suggested that the known biomarkers and the diagnostic scales are unreliable for the diagnosis of Kampo‐induced liver injury (KMILI).","PeriodicalId":23213,"journal":{"name":"Traditional & Kampo Medicine","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-07-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"91306923","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Tomofumi Shimizu, K. Murakami, Chinami Matsumoto, T. Kido, Y. Isohama
In Japan, goreisan (GRS) is used to alleviate cerebral edema and relieve headaches. Although improvement of water maldistribution in the brain may be one of the mechanisms of action of GRS for cerebral edema and headache, scientific evidence is limited. Here, we aimed to investigate the action mechanism of GRS against cerebral edema and headaches, focusing on water dynamics in the brain.
{"title":"Goreisan alleviates cerebral edema: Possibility of its involvement in inhibiting aquaporin‐4 function","authors":"Tomofumi Shimizu, K. Murakami, Chinami Matsumoto, T. Kido, Y. Isohama","doi":"10.1002/tkm2.1380","DOIUrl":"https://doi.org/10.1002/tkm2.1380","url":null,"abstract":"In Japan, goreisan (GRS) is used to alleviate cerebral edema and relieve headaches. Although improvement of water maldistribution in the brain may be one of the mechanisms of action of GRS for cerebral edema and headache, scientific evidence is limited. Here, we aimed to investigate the action mechanism of GRS against cerebral edema and headaches, focusing on water dynamics in the brain.","PeriodicalId":23213,"journal":{"name":"Traditional & Kampo Medicine","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-06-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"82665081","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：